CU23915B1 - Granulación en húmedo utilizando un agente secuestrante de agua - Google Patents

Granulación en húmedo utilizando un agente secuestrante de agua

Info

Publication number
CU23915B1
CU23915B1 CU2010000089A CU20100089A CU23915B1 CU 23915 B1 CU23915 B1 CU 23915B1 CU 2010000089 A CU2010000089 A CU 2010000089A CU 20100089 A CU20100089 A CU 20100089A CU 23915 B1 CU23915 B1 CU 23915B1
Authority
CU
Cuba
Prior art keywords
wet
granulation
sequencing agent
water
water sequencing
Prior art date
Application number
CU2010000089A
Other languages
English (en)
Other versions
CU20100089A7 (es
Inventor
Thomas Sun
Ray Lo
Original Assignee
Rigel Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40623940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23915(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals filed Critical Rigel Pharmaceuticals
Publication of CU20100089A7 publication Critical patent/CU20100089A7/es
Publication of CU23915B1 publication Critical patent/CU23915B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Se describen tabletas que comprenden formulaciones estables hidrolíticamente de sal disódica de (6-(5-fluor-2-(3,4,5-trimetoxifenilamino)pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato (compuesto 1) preparado por un proceso de granulación en húmedo.
CU2010000089A 2007-11-07 2010-05-05 Granulación en húmedo utilizando un agente secuestrante de agua CU23915B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98623707P 2007-11-07 2007-11-07
PCT/US2008/082618 WO2009061909A2 (en) 2007-11-07 2008-11-06 Wet granulation using a water sequestering agent

Publications (2)

Publication Number Publication Date
CU20100089A7 CU20100089A7 (es) 2011-10-05
CU23915B1 true CU23915B1 (es) 2013-07-31

Family

ID=40623940

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000089A CU23915B1 (es) 2007-11-07 2010-05-05 Granulación en húmedo utilizando un agente secuestrante de agua

Country Status (34)

Country Link
US (3) US8263122B2 (es)
EP (1) EP2217241B1 (es)
JP (1) JP5567487B2 (es)
KR (2) KR20150129067A (es)
CN (1) CN101998857A (es)
AU (1) AU2008323938B2 (es)
BR (1) BRPI0820389A2 (es)
CA (1) CA2704474C (es)
CO (1) CO6280491A2 (es)
CR (1) CR11476A (es)
CU (1) CU23915B1 (es)
CY (1) CY1122163T1 (es)
DK (1) DK2217241T3 (es)
DO (1) DOP2010000136A (es)
EA (1) EA020210B1 (es)
EC (1) ECSP10010233A (es)
ES (1) ES2672519T3 (es)
HN (1) HN2010000930A (es)
HR (1) HRP20181174T1 (es)
HU (1) HUE039193T2 (es)
IL (1) IL205204A (es)
LT (1) LT2217241T (es)
MX (1) MX2010004733A (es)
MY (1) MY169761A (es)
NI (1) NI201000078A (es)
NZ (1) NZ585913A (es)
PL (1) PL2217241T3 (es)
PT (1) PT2217241T (es)
RS (1) RS57525B1 (es)
SG (1) SG185961A1 (es)
SI (1) SI2217241T1 (es)
TR (1) TR201807879T4 (es)
UA (1) UA102825C2 (es)
WO (1) WO2009061909A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080223392A1 (en) * 2007-03-14 2008-09-18 L'oreal Process for relaxing or straightening hair
GB0814688D0 (en) 2008-08-12 2008-09-17 Knauf Insulation Thermal insulation product
CA2777225C (en) * 2009-09-07 2019-06-11 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
BR112012020585A2 (pt) * 2010-02-24 2018-04-17 Auspex Pharmaceuticals Inc composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
PT2736487T (pt) * 2011-07-28 2019-02-13 Rigel Pharmaceuticals Inc Novas formulações de (trimetoxifenilamino) pirimidinilo
US20180296579A1 (en) 2015-04-24 2018-10-18 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5358652A (en) * 1992-10-26 1994-10-25 Ethyl Petroleum Additives, Limited Inhibiting hydrolytic degradation of hydrolyzable oleaginous fluids
EP1051181B1 (en) * 1997-12-31 2004-03-17 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1487419A2 (en) * 2002-03-20 2004-12-22 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
ITMI20040498A1 (it) * 2004-03-16 2004-06-16 Solvay Solexis Spa Composizioni granulari
BRPI0606318B8 (pt) * 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions

Also Published As

Publication number Publication date
ECSP10010233A (es) 2010-07-30
RS57525B1 (sr) 2018-10-31
CY1122163T1 (el) 2020-07-31
UA102825C2 (ru) 2013-08-27
DOP2010000136A (es) 2010-09-30
US20130189359A1 (en) 2013-07-25
AU2008323938A1 (en) 2009-05-14
KR20150129067A (ko) 2015-11-18
EP2217241A2 (en) 2010-08-18
CR11476A (es) 2010-08-27
CU20100089A7 (es) 2011-10-05
WO2009061909A2 (en) 2009-05-14
HRP20181174T1 (hr) 2018-09-21
HUE039193T2 (hu) 2018-12-28
CA2704474A1 (en) 2009-05-14
MX2010004733A (es) 2010-06-25
MY169761A (en) 2019-05-15
HN2010000930A (es) 2012-11-12
IL205204A0 (en) 2010-12-30
IL205204A (en) 2015-07-30
SI2217241T1 (sl) 2018-10-30
CN101998857A (zh) 2011-03-30
US8263122B2 (en) 2012-09-11
AU2008323938B2 (en) 2014-04-10
KR101663838B1 (ko) 2016-10-07
ES2672519T3 (es) 2018-06-14
KR20100088622A (ko) 2010-08-09
EP2217241B1 (en) 2018-04-25
JP5567487B2 (ja) 2014-08-06
CO6280491A2 (es) 2011-05-20
US8652492B2 (en) 2014-02-18
EA201070570A1 (ru) 2010-10-29
CA2704474C (en) 2016-04-26
PL2217241T3 (pl) 2018-11-30
TR201807879T4 (tr) 2018-06-21
PT2217241T (pt) 2018-06-11
BRPI0820389A2 (pt) 2015-05-19
WO2009061909A3 (en) 2009-11-05
US20090123539A1 (en) 2009-05-14
LT2217241T (lt) 2018-09-10
EA020210B1 (ru) 2014-09-30
NI201000078A (es) 2011-05-16
JP2011503010A (ja) 2011-01-27
US20120288543A1 (en) 2012-11-15
US8372415B2 (en) 2013-02-12
DK2217241T3 (en) 2018-08-06
SG185961A1 (en) 2012-12-28
NZ585913A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
CU23915B1 (es) Granulación en húmedo utilizando un agente secuestrante de agua
BRPI0412516A (pt) sal isetionato de um seletivo inibidor cdk4
NZ590777A (en) PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
BR112014032338A2 (pt) cristais de sal
BRPI0820308A8 (pt) composições farmacêuticas
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
MX2021012478A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
EA201491675A1 (ru) Новые вещества
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
NO20091133L (no) Anvendelse av 2-6-(3-amino-piperidin-L-yl)-3-metyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmetyl-4-fluor-benzonitril
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
HRP20070534T3 (en) Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
MX2010006212A (es) Compuestos organicos.
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MA201637385A2 (fr) Inhibiteurs de diacylglycérol-acyltransférase 2
BR112012031297A2 (pt) formulações de spray oral e métodos para administração de sildenafil
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
NZ730189A (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
ECSP12011923A (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY31588A1 (es) Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
MA35347B1 (fr) Procedes therapeuiques

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)